MUNICH, Sept 3 (Reuters) - Sanofi-Aventis's experimental heart drug Multaq (dronedarone) decreases the risk of stroke by more than a third in patients with atrial fibrillation researchers said on Wednesday at the European Society of Cardiology meeting.
More from Ben Hirschler
In 2006 the FDA rejected Multaq , evidently unsatisfied with the data provided at that time to support its application. The company refiled and won a priority review last month.
Ahh! Those wasted patent years!
No comments:
Post a Comment